Statins vs PCSK9 Inhibitors for High Cholesterol

Research-informed explainer — last updated April 12, 2026

For most people with high LDL cholesterol, a statin is still the starting point — and for many, it's enough. PCSK9 inhibitors are a powerful newer option that can cut LDL far lower than statins alone, but they're injectable, expensive, and designed primarily for patients at the highest cardiovascular risk. The question of which one is "better" depends almost entirely on where you are on the risk spectrum.

This explainer covers how statins and PCSK9 inhibitors work, what the major cardiovascular trials showed, and how doctors decide when to add or switch. It draws on research from cardiologists at Cleveland Clinic, Mount Sinai, and Mayo Clinic, including contributors to the landmark ODYSSEY OUTCOMES trial and the ACC/AHA guidelines on acute coronary syndromes.

What's the difference?

Statins block an enzyme the liver uses to make cholesterol (HMG-CoA reductase). When the liver makes less cholesterol, it pulls more LDL from the blood — typically reducing LDL by 30–60% depending on the drug and dose. They're generic, taken as a daily pill, and covered by virtually every insurance plan. Statins have decades of trial data behind them and a well-characterized side effect profile.

PCSK9 inhibitors work differently. PCSK9 is a protein that degrades LDL receptors on liver cells; when PCSK9 is blocked, more receptors remain active and clear more LDL from the blood. The two main drugs in this class — evolocumab (Repatha) and alirocumab (Praluent) — are injectable monoclonal antibodies given every two or four weeks. They can reduce LDL by 50–65% on top of whatever a statin is already doing, pushing many patients into the 20–40 mg/dL range. The tradeoff is cost (roughly $5,000–7,000 per year before discounts or insurance coverage) and the fact that they require injections.

At a glance

What the major trials showed

The key trial for PCSK9 inhibitors in cardiovascular prevention is ODYSSEY OUTCOMES, a randomized controlled study that enrolled patients who had suffered an acute coronary syndrome (heart attack or unstable angina) and were already on high-intensity statin therapy. Researchers added alirocumab or placebo on top of that statin regimen. Patients who received alirocumab had fewer major adverse cardiovascular events — including heart attack, stroke, and cardiovascular death — compared to those on statin alone [1].

The trial's significance is specific: PCSK9 inhibitors work in addition to statins, not instead of them. The comparison in the trial wasn't statin versus PCSK9 inhibitor — it was the combination versus statins alone in people who had already had a cardiovascular event. That makes the ODYSSEY OUTCOMES findings most directly relevant to people in secondary prevention (already have heart disease) rather than primary prevention (trying to avoid a first event).

For patients with elevated triglycerides on top of statin therapy, the REDUCE-IT trial tested a high-dose omega-3 fatty acid (icosapent ethyl) added to statin treatment and found significant reduction in ischemic events, including cardiovascular death [2]. This illustrates a broader principle: statin therapy is often the foundation, with other agents added when standard LDL-lowering isn't enough.

When do guidelines recommend adding a PCSK9 inhibitor?

The ACC/AHA guidelines on managing high-risk cardiovascular patients generally reserve PCSK9 inhibitors for specific categories — not broad high-cholesterol populations [3]. The clearest indications are:

• Secondary prevention patients (prior heart attack, stroke, or arterial disease) whose LDL remains above 70 mg/dL despite maximally tolerated statin therapy
• Familial hypercholesterolemia — an inherited condition that causes very high LDL from birth; these patients often can't reach target LDL with statins alone
• Statin intolerance — patients who can't tolerate statins at effective doses due to muscle pain or other side effects

The approach follows a hierarchy: start with statins (usually high-intensity), add ezetimibe if LDL remains high, then consider a PCSK9 inhibitor if the target still isn't met. Most primary-prevention patients with elevated cholesterol but no prior cardiovascular events don't need to skip ahead to a PCSK9 inhibitor.

What about statin risks?

Statins are generally well-tolerated, but they're not without issues. Muscle aches (myalgia) affect 5–10% of patients in clinical practice, though the rate in blinded trials is lower. A small increase in type 2 diabetes risk has been documented in meta-analyses. Serious complications like rhabdomyolysis are rare.

Research on cardiovascular drug safety has made clear why rigorous outcome trials matter for lipid-lowering drugs. A meta-analysis of rosiglitazone — a diabetes drug — showed that a medication which improves glucose control can simultaneously increase cardiovascular event risk [6], a finding that prompted the FDA to require cardiovascular outcome trials for new diabetes therapies. The same discipline now applies to lipid-lowering agents. PCSK9 inhibitor trials like ODYSSEY OUTCOMES were designed specifically to answer whether lowering LDL further actually translates to fewer heart attacks and strokes — not just whether the number on a lab report goes down [1].

Cost and access

The out-of-pocket cost gap between statins and PCSK9 inhibitors is substantial. High-potency statins like rosuvastatin (Crestor) and atorvastatin (Lipitor) are available as generics for a few dollars a month. PCSK9 inhibitors carry list prices in the thousands per year, though manufacturer patient assistance programs and insurer coverage have brought actual out-of-pocket costs down significantly for eligible patients. Most insurers require prior authorization and documentation of inadequate statin response before approving PCSK9 inhibitors — so expect some administrative paperwork if your doctor recommends one.

Questions to ask your doctor

• What is my current LDL, and what's the target for someone with my risk level?
• Am I on the highest dose of statin I can tolerate, or is there room to intensify first?
• Have I tried ezetimibe? Is there a reason to skip that step?
• Do I have familial hypercholesterolemia or a prior cardiovascular event that would make a PCSK9 inhibitor a stronger option?
• If you recommend a PCSK9 inhibitor, can you help me navigate the prior authorization process?
• If I'm not tolerating my current statin, is switching to a different statin worth trying before adding an injectable medication?

The bottom line

Statins are the first-line treatment for high LDL cholesterol, and for most people — even those with elevated cardiovascular risk — they're sufficient when taken at adequate doses. PCSK9 inhibitors are a genuinely effective add-on for the right patient: someone who's already had a heart attack or has familial hypercholesterolemia and still can't get LDL low enough on statins. The research doesn't support choosing one over the other as if they're alternatives; for most patients they work best as a sequence, not a competition.

If your LDL remains elevated despite maximal statin therapy, that conversation about what comes next belongs with a cardiologist or lipid specialist who has managed similar patients.